BHVN (Biohaven) Total Stockholders Equity : $259.50 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Biohaven Total Stockholders Equity?

Biohaven's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $259.50 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Biohaven's Book Value per Share for the quarter that ended in Mar. 2025 was $2.54. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Biohaven's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.14.

Biohaven Total Stockholders Equity Historical Data

The historical data trend for Biohaven's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Total Stockholders Equity Chart

Biohaven Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

16.78

34.69

538.77

427.98

423.44

Biohaven Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial											301.45	383.74	316.01	423.44	259.50

Biohaven (NYSE:BHVN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Biohaven's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(259.495	-	0)	/	102.104
	=	2.54

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Biohaven's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.708	+	30.804)	/	259.495
	=	0.14

Biohaven Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Biohaven's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Biohaven Pharmaceuticals, Inc, 215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohaven.com

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Executives

John W Childs	director	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET, NEW HAVEN CT 06510
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET, NEW HAVEN CT 06510